GlassScriptPhysician profile
Jennifer Kamp
NPI 1902523749
$4,638.85
in general payments reported to CMS, 2019-2025
41 companies · $312 in 2025
The $312 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $385 · 2023: $2,481 · 2024: $1,460 · 2025: $312.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,253.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,253.36 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $745.27 | 2022-2025 | |
| Novo Nordisk INC | $481.36 | 2022-2024 | Rybelsus, Ozempic, Wegovy |
| Astrazeneca Pharmaceuticals LP | $456.11 | 2023-2024 | Farxiga, Breztri, Flumist Quadrivalent |
| Novartis Pharmaceuticals Corporation | $286.75 | 2024-2025 | |
| Lilly USA, LLC | $238.78 | 2023-2024 | Mounjaro, Jardiance, Zepbound |
| Amgen INC. | $226.71 | 2023-2024 | Prolia, Evenity, Repatha |
| Janssen Pharmaceuticals, INC | $213.72 | 2023-2024 | Spravato, Xarelto |
| Otsuka America Pharmaceutical, INC. | $190.20 | 2023-2024 | Rexulti |
| Glaxosmithkline, LLC. | $165.37 | 2023-2025 | Shingrix, Arexvy, Trelegy Ellipta |
| Boehringer Ingelheim Pharmaceuticals, INC. | $152.36 | 2023-2024 | Jardiance |
| Corcept Therapeutics | $148.72 | 2023-2024 | Korlym |
| Exact Sciences Corporation | $131.54 | 2023 | Cologuard Collection Kit |
| Astellas Pharma US INC | $114.25 | 2023-2024 | Veozah, Myrbetriq |
| Axsome Therapeutics, INC. | $92.99 | 2023-2024 | Auvelity |
| Janssen Biotech, INC. | $89.74 | 2022-2023 | Tremfya, Simponi Aria |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $73.73 | 2023-2024 | Belsomra, Verquvo, Steglatro |
| Bayer Healthcare Pharmaceuticals INC. | $66.95 | 2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $65.13 | 2023-2024 | Trintellix |
| Inspire Medical Systems, INC. | $63.02 | 2023-2024 | Inspire |
| Antares Pharma, INC. | $59.81 | 2023-2024 | Xyosted, Tlando, Nocdurna |
| Pfizer INC. | $47.65 | 2023 | |
| Sanofi-Aventis U.S. LLC | $42.18 | 2023-2025 | |
| Dynavax Technologies Corporation | $41.53 | 2023-2024 | Heplisav-B |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $37.55 | 2023-2024 | Xifaxan, Trulance |
| Tris Pharma INC | $36.88 | 2024 | Dyanavel Xr |
| Aimmune Therapeutics, INC. | $33.26 | 2024 | |
| Nestle Healthcare Nutrition INC. | $32.91 | 2023 | |
| Dexcom, INC. | $32.05 | 2023-2024 | Dexcom G6 Transmitter |
| Currax Pharmaceuticals LLC | $28.79 | 2023-2024 | Contrave |
| Mallinckrodt Hospital Products INC. | $28.04 | 2022 | |
| Inari Medical, INC. | $25.76 | 2023 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Xeris Pharmaceuticals, INC. | $24.94 | 2023 | Gvoke Hypopen |
| Pacira Pharmaceuticals Incorporated | $24.66 | 2023 | Exparel, Iovera, Zilretta |
| Phathom Pharmaceuticals, INC. | $22.15 | 2024 | Voquezna |
| Organon LLC | $20.43 | 2025 | Nexplanon |
| Alnylam Pharmaceuticals INC. | $19.51 | 2023 | Oxlumo |
| Shield Therapeutics INC | $16.71 | 2023 | |
| Esperion Therapeutics, INC. | $16.68 | 2024 | Nexletol |
| Sanofi Pasteur INC. | $15.51 | 2023 | |
| Seqirus USA INC | $14.88 | 2024 | Fluad, Flucelvax |
| Lundbeck LLC | $14.27 | 2024 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Kamp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.